| 000 | 01433 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250516041458.0 | ||
| 264 | 0 | _c20111123 | |
| 008 | 201111s 0 0 eng d | ||
| 022 | _a1744-7674 | ||
| 024 | 7 |
_a10.1517/13543776.2011.587959 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMattmann, Margrith E | |
| 245 | 0 | 0 |
_aInhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape. _h[electronic resource] |
| 260 |
_bExpert opinion on therapeutic patents _cSep 2011 |
||
| 300 |
_a1309-38 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAdenosine Triphosphate _xantagonists & inhibitors |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xchemical synthesis |
| 650 | 0 | 4 |
_aBinding, Competitive _xdrug effects |
| 650 | 0 | 4 |
_aBiological Products _xpharmacology |
| 650 | 0 | 4 |
_aBiotransformation _xdrug effects |
| 650 | 0 | 4 |
_aCentral Nervous System Diseases _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aOncogene Protein v-akt _xantagonists & inhibitors |
| 650 | 0 | 4 | _aPatents as Topic |
| 650 | 0 | 4 | _aSmall Molecule Libraries |
| 700 | 1 | _aStoops, Sydney L | |
| 700 | 1 | _aLindsley, Craig W | |
| 773 | 0 |
_tExpert opinion on therapeutic patents _gvol. 21 _gno. 9 _gp. 1309-38 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/13543776.2011.587959 _zAvailable from publisher's website |
| 999 |
_c20893855 _d20893855 |
||